Skip to main content
. 2022 Jan 7;12:806570. doi: 10.3389/fphar.2021.806570

FIGURE 3.

FIGURE 3

Emerging Therapeutics Targets in MPM. STAT3, KDM4A, heparanase are promising new thereapeutic targets in MPM. Clinical stage inhibitors are indicated and treatment may benefit from combination with navitoclax.